News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

ReGen Therapeutics Plc (LS:RGT) Retains Sky Investor Relations To Raise Awareness In The U.S.

10/19/2005 5:10:30 PM

NEW YORK, March 18 /PRNewswire/ -- United Kingdom-based ReGen Therapeutics Plc (AIM: RGT), a biotechnology company that is developing a treatment for Alzheimer's disease, announced today that it has retained Wall Street-based Sky Investor Relations to raise its visibility in the U.S.

ReGen Therapeutics has had a U.S. presence through its scientific research and development activities, which are being conducted at the University of Texas Medical Branch in Galveston, Texas. ReGen's principal drug, Colostrinin(TM), is being developed as a treatment for Alzheimer's disease. Colostrinin(TM) is patented in four countries including the Untied States. ReGen has been publicly traded on the AIM market, a division of the London Stock Exchange, since 2000.

"We anticipate that the U.S. will be a primary market for our Alzheimer's drug. With the support of Sky IR we hope to increase recognition of our company and Colostrinin(TM) amongst the American medical community, trade media, and U.S.-based financial professionals," stated ReGen Therapeutics Executive Chairman, Mr. Percy Lomax.

"We are very excited to represent ReGen Therapeutics to our extensive network of business professionals and journalists in the healthcare field. Alzheimer's disease plagues an estimated 10 million people in industrialized nations alone and therefore ReGen and its development of an Alzheimer's treatment warrant further attention from the healthcare community in the U.S.," stated Ms. Laurel Moody, President of Sky Investor Relations. ReGen Therapeutics will be hosting an introductory presentation in New York City on March 24, 2004 at the Plaza Hotel. Those interested in attending the presentation may contact Ms. Christine Petraglia of Sky IR at 212-440-5000.

About ReGen Therapeutics Plc

ReGen Therapeutics is a biotechnology company that develops and explores the use of Colostrinin(TM), for the treatment of Alzheimer's disease and other neurological disorders. Colostrinin(TM) is based on colostrum derived from sheep and is the mammal's first milk after the birth of an offspring. The Company is currently pursuing a dual-track commercialization strategy through the development and marketing of prescription Colostrinin(TM), as well as a Colostrinin(TM)-based nutraceutical product.

About Sky Investor Relations

Sky Investor Relations is a leading Wall Street-based investor and public relations firm servicing the needs of micro and small-cap publicly traded companies. Sky IR has offices in London and Los Angeles, in addition to its headquarters in New York City. Through investment community contacts, media placements and corporate positioning and communications, Sky IR raises the visibility of its clients and supports enhanced shareholder value. Sky IR is a subsidiary of Sky Venture Capital.

Neither ReGen nor any of its existing shareholders is offering any securities for sale in the United States. This press release is not an offer to sell or a solicitation of offers to buy any securities in the United States. ReGen's securities are not registered under the U.S. Securities Act of 1933.

Statements in this press release other than statements of historical fact, including statements regarding the company's plans, beliefs, and estimates as to projected market size are "forward-looking statements." Such statements are subject to certain risks and uncertainties, and actual results could differ materially from expected results. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

ReGen Therapeutics Plc; Sky Investor Relations

CONTACT: Laurel Moody of Sky Investor Relations, +1-212-440-5000,

Read at

Related News

comments powered by Disqus